Ergoteles LLC: LAB position timeline
Available 13F reports, 13D and 13G stakes and each Form 3, 4 and 5 line of Ergoteles LLC on LAB, newest first. How the timeline and the estimate are built.
Ergoteles LLC held 0 LAB shares at 2023-03-31 per its 13F-HR filed 2023-05-10.
the latest 13F is the newest step
- period ended2023-03-3113F 0 sharesChange vs previous 13F -18,319 shares
13F-HR 0001569136-23-000002 filed by Ergoteles LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
Exited: the 13F for this period no longer lists the position.
- period ended2022-12-3113F 18,319 sharesChange vs previous 13F -178,578 shares
<0.01% of the 13F portfolio, value $21,433.
13F-HR 0001569136-23-000001 filed by Ergoteles LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2022-09-3013F 196,897 sharesChange vs previous 13F -151,503 shares
0.01% of the 13F portfolio, value $217,000.
13F-HR 0001569136-22-000007 filed by Ergoteles LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2022-06-3013F 348,400 sharesChange vs previous 13F +348,400 shares
0.02% of the 13F portfolio, value $557,000.
13F-HR 0001569136-22-000006 filed by Ergoteles LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2022-03-3113F 0 sharesChange vs previous 13F -54,948 shares
13F-HR 0001569136-22-000005 filed by Ergoteles LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
Exited: the 13F for this period no longer lists the position.
- period ended2021-12-3113F 54,948 sharesChange vs previous 13F not available
0.01% of the 13F portfolio, value $215,000.
13F-HR 0001569136-22-000002 filed by Ergoteles LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).